Phenobarbital Sodium Injection Recalled for Sterility Assurance Deviations
Vitae Enim Vitae Scientific is recalling Phenobarbital Sodium Injection nationally due to deviations from manufacturing practices that compromise sterility assurance on this injectable drug.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable drug with questioned sterility due to CGMP deviations. No illnesses or injuries have been reported. Per the rubric, lack of sterility in an injectable product represents a risk-of-harm situation where injury has not yet been reported, scoring 3 (High).
Plain-English summary
Phenobarbital Sodium Injection USP 65mg/mL is being recalled by Vitae Enim Vitae Scientific, Inc., manufactured for Cameron Pharmaceuticals, LLC. The recall affects approximately 26,347 boxes distributed nationwide in the United States.
The recall was initiated due to deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of these injectable products. Phenobarbital sodium is a prescription medication administered by intramuscular injection.
The recall includes multiple lot numbers across two packaging configurations (25x1mL vials and 3x1mL vials per box), with expiration dates ranging from March 2022 through August 2024.
Healthcare providers and patients who have this product should stop using it and contact their pharmaceutical suppliers for replacement stock. For guidance on ongoing treatment needs, consult with a healthcare provider.
The recalled product
- Product
- PHENOBARBITAL SODIUM (PHENOBARBITAL SODIUM)
- Brand
- PHENOBARBITAL SODIUM
- Manufacturer
- Vitae Enim Vitae Scientific, Inc.
- Category
- Drug — Injectable
- Hazard
- lack-of-sterility
- microbial-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: a) 20VPSI007
- Exp 3/31/2022
- 20VPSI015
- Exp 5/30/2022
- 20VPSI018
- Exp 6/1/2022
- 20VPSI032
- Exp 11/30/2022
- 21VPSI002
- 21VPSI003
- Exp 1/31/2023
- 21VPSI006
- Exp 3/31/2023
- 21VPSI012
- 21VPSI020
- Exp 5/31/2023
- 21VPSI035
- Exp 7/31/2023
- 21VPSI037
- 21VPSI038
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · PHENOBARBITAL SODIUM
- HighPhenobarbital Sodium Injection recalled for manufacturing sterility defect
FDA (Drugs) · 2022-04-13
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27